
Custom crystal commemorating the approval by the FDA of Ingrezza, the first drug approved for the treatment of the neurological condition tardive dyskinesia. (8ALJ380)

Custom crystal commemorating the approval by the FDA of Ingrezza, the first drug approved for the treatment of the neurological condition tardive dyskinesia. (8ALJ380)
"*" indicates required fields